Dear Well-wishers,

I begin writing this May 2018 edition of Oviya MedSafe’s newsletter with the satisfaction that ‘IndUS Drug Safety’, our recently announced initiative aimed at demystifying the Indian and the US FDA pharmacovigilance compliance requirements for the pharmaceutical industry, has picked up momentum resulting in delegate registrations flowing in for this day-long workshop which is to be held at Hotel Kohinoor Continental, Mumbai on Friday, 29th June 2018!

While thanking leading pharmaceutical news portals Pharmabiz and Express Pharma for having published our press release on ‘IndUS Drug Safety’, I am happy to add that the detailed agenda of the workshop is now available. The agenda, along with the registration form, may be downloaded from Oviya MedSafe’s Downloads Page. For any more information, please do not hesitate to contact us at or +918220763222.

At this juncture, I believe it may be relevant for me to briefly recall some of the unique approaches we adopted in 2012 which helped Oviya MedSafe metamorphose from its humble beginnings into an organization of pharmacovigilance excellence that it is today. Firstly, we decided to comprehensively train our carefully selected entry level staff in several aspects of pharmacovigilance for a period of three months (as against the industry average of about two weeks) before being entrusted with client work. This meant that we needed to invest a lot of effort in this direction but we were mentally prepared for it as we had made up our mind that the ’boutique consultancy’ model we adopted for our organization would succeed only if we developed our people without cutting corners. Secondly, we put in measures of checks and balances to ensure that the candidates were evaluated at every stage of their learning before moving to the next. This step helped us ensure that both the quality and the productivity of the team met our expectations.

Thirdly, we consciously avoided the options of charging the trainees or extending staff augmentation services to other organizations, as an attempt to address our overheads. Rather, we made our team confident of themselves and assured them that they would continue to be part of Oviya MedSafe and keep growing in the organization provided they cleared their assessments without compromise. This gave rise to the work culture of our team members being strongly rooted to Oviya MedSafe, which meant that we would have very less need to hire candidates from other organizations. It eventually turned out to be true. I personally feel that our strong home-grown capacity-building capability is one of the key reasons for the dynamism Oviya MedSafe is recognized for. It is no wonder that Oviya MedSafe continued to gain mileage as an organization capable of providing several levels of structured customized training in pharmacovigilance, despite its exponential growth as a conventional provider of drug safety services as well.

The quick thoughts I have jotted down above may mean more in the context of Oviya MedSafe’s August 2016December 2016May 2017August 2017 and January 2018 newsletter editions which highlight Oviya MedSafe’s core values ‘continuous learning to empower clients’ and ‘perpetual capability-building‘. I encourage you to read these newsletter editions at your convenience which I am sure will make you want to register for ‘IndUS Drug Safety‘. I am excitedly looking forward to travel with my team to Mumbai to conduct this workshop.

On another note, I am delighted to share some snaps from the ‘OPPI Medical Forum 2018’ event held in Mumbai on 3rd May 2018 in which I was an invited speaker and panelist. This event conducted by the Organisation of Pharmaceutical Producers of India gave me the honour of sharing the stage with Dr V G Somani, Joint Drugs Controller (India), in the panel discussion that ensued. Dr Deepa Arora (Lupin) and Dr Jamal Baig (MSD) were the other panelists in the session which was hosted by Ms Indu Nambiar (Boehringer Ingelheim) and Ms Sofi Joseph (Serdia). Please click here to view and/or download the photos.

Before signing off, I wanted to reiterate that the 2018 edition of the Indian Pharmacovigilance Day conference which I am to Chair for the third time is being organized at Hotel Peninsula Grand, Mumbai on Friday, 27th July 2018. The agenda for this conference is under finalization and, as in the previous editions, this will have the Who’s Who of the pharmacovigilance domain across several organizations as speakers and panelists. Please keep watching the conference website for more information. I have also been asked by the organizers (Italy-based LS Academy, a business unit of EasyB srl) to inform my network that early bird discounts would be applicable for all registrations made before 30th June 2018. For further details, please contact EasyB at or +917598815311.

Thanking you for your patient reading and waiting to meet you in June 2018,

With thanks & regards,
Dr J Vijay Venkatraman

Managing Director & CEO,
Oviya MedSafe Pvt Ltd,
Coimbatore, India
Phone: +91-422-2444442

Oviya MedSafe UK Ltd,
London, UK
Phone: +44-8452-733839

Follow us on: FacebookLinkedIn & Twitter

Leave a comment

Your email address will not be published. Required fields are marked *